Trial Profile
A 12-week study of TS-071, a selective SGLT2 inhibitor, in Japanese patients with type 2 diabetes mellitus.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 27 Sep 2021
Price :
$35
*
At a glance
- Drugs Luseogliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 12 Sep 2021 Results of pooled analysis of three studies JapicCTI090908, JapicCTI101191 and JapicCTI11166116 published in the Journal of Clinical Pharmacology
- 16 Sep 2011 Results presented at the 47th Annual Meeting of the European Association for the Study of Diabetes.
- 01 Jul 2011 New trial record